/APLM
APLM Stock - Apollomics, Inc.
Healthcare|BiotechnologyNASDAQ
$16.73+10.62%
+$1.60 (+10.62%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.63
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.48
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $18.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APLM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.56 – $16.89
TARGET (TP)$19.23
STOP LOSS$15.39
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.80
52W High$42.12
52W Low$3.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $198,000 | $821,000 | $323,000 | $2,000 | $1.84M |
| Gross Profit | $198,000 | $821,000 | $323,000 | $2,000 | $1.84M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-42,136,000 | $-54,013,000 | $-45,081,000 | $-50,857,000 | $-40,646,000 |
| Net Income | $-53,858,000 | $-172,601,000 | $-240,811,000 | $-94,797,000 | $-74,820,000 |
| Net Margin | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | -4070.7% |
| EPS | $-52.80 | $-231.99 | $-61.60 | $-23.45 | $-20.70 |
Company Overview
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
APLMBeat Rate
0%
Last 3 quarters
Avg Surprise
-111236.2%
EPS vs Estimate
Beats / Misses
0/3
Last 12 quarters
Latest EPS
$-16.92
Q4 2024
EPS Surprise History
Q2 22
No data
Q4 22
No data
Q3 23
-159533.5%
$-255.41vs$-0.16
Q3 23
-159275.0%
$-255.00vs$-0.16
Q4 23
No data
Q1 24
-14900.0%
$-24.00vs$-0.16
Q2 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 3, 2025 | — | — | — | — |
Q2 2025 | Apr 3, 2025 | — | — | — | — |
Q4 2024 | Dec 31, 2024 | — | $-16.92 | — | — |
Q2 2024 | Jun 30, 2024 | — | $-37.56 | — | — |
Q1 2024 | Mar 28, 2024 | $-0.16 | $-24.00 | -14900.0% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $-24.39 | — | — |
Q3 2023 | Sep 28, 2023 | $-0.16 | $-255.00 | -159275.0% | ✗ MISS |
Q3 2023 | Jul 28, 2023 | $-0.16 | $-255.41 | -159533.5% | ✗ MISS |
Q2 2023 | Apr 28, 2023 | — | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $-273.51 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-25.45 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-17.58 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-8.75 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-49.88 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-2.41 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-44.01 | — | — |
Latest News
On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations
📉 NegativeBenzinga•Dec 12, 2025, 04:43 PM
APLM stock has given up its prior gain. Apollomics shares were trading higher after the company announced it entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment.
➖ NeutralBenzinga•Dec 8, 2025, 03:46 PM
CORRECTION: Apollomics entered into a settlement agreement on Nov. 19
➖ NeutralBenzinga•Dec 8, 2025, 02:31 PM
Apollomics shares are trading higher after the company announced it entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment.
📈 PositiveBenzinga•Dec 8, 2025, 02:30 PM
Apollomics Enters Into Settlement Agreement With TWVC Goldlink Partners Investment And TWVC Panglin Group Investment; To Pay $5M In Cash And $879,757.78 In Associated Legal expenses
📉 NegativeBenzinga•Nov 19, 2025, 09:11 PM
Reported Earlier, Apollomics Appoints Ya Chi Claudia Huang To Board And Committees Following Resignation Of Po Jen Hsueh
➖ NeutralBenzinga•Nov 18, 2025, 07:04 AM
Apollomics Receives $3.9M Payment From LaunXP, Maintains Active Collaboration On Vebreltinib Development
📈 PositiveBenzinga•Oct 21, 2025, 03:21 PM
Nasdaq Cancels Delisting Hearing For Apollomics, Confirms Compliance With Continued Listing Standards
📈 PositiveBenzinga•Oct 15, 2025, 06:40 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 15, 2025, 12:55 PM
Nasdaq To Resume Trading In Apollomics Shares And Warrants On October 15, 2025
➖ NeutralBenzinga•Oct 14, 2025, 08:08 PM•Also: ,
Frequently Asked Questions about APLM
What is APLM's current stock price?
Apollomics, Inc. (APLM) is currently trading at $16.73 per share. The stock has moved +10.62% today.
What is the analyst price target for APLM?
No analyst price targets are currently available for this stock.
What sector is Apollomics, Inc. in?
Apollomics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is APLM's market cap?
Apollomics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does APLM pay dividends?
No, Apollomics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to APLM for comparison